Related Experiment Video
Updated: Jul 16, 2026
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
When Pneumonia Leads to Sepsis: Clinical Phenotypes and Therapeutic Challenges
Ignacio Martin-Loeches1, Marc Leone2, Luis Felipe Reyes3
1Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, Dublin, Ireland; School of Medicine, Trinity College Dublin, College Green, Dublin, Ireland; Trinity Centre for Biomedical Engineering, Dublin, Ireland.
Background:
Severe pneumonia is a leading cause of sepsis and mortality in critically ill patients. Pathogen-centred frameworks alone do not explain the marked heterogeneity in clinical presentation and outcomes. Increasing evidence supports a model in which disease progression reflects the interaction between microbial burden, host-response dysregulation, and environmental factors, including viral co-infection and fungal opportunism. This review synthesises current advances in pneumonia-to-sepsis progression, focusing on clinical phenotypes, host-response dynamics, and therapeutic implications.
Methods:
This narrative review draws on recent literature, prioritising studies from the past decade, particularly the last 2-3 years. Sources included PubMed-indexed publications, clinical trials, observational studies, and consensus guidelines addressing severe community-acquired and nosocomial pneumonia, sepsis, host-response biomarkers, and emerging therapies. Selection was based on relevance to critically ill populations and mechanistic insights into host-pathogen interactions.
Results:
Pneumonia is increasingly recognised as a biologically heterogeneous syndrome characterised by distinct host-response phenotypes, ranging from hyperinflammatory to immunosuppressed states, which shape clinical trajectories. Viral infections and fungal opportunism contribute to disease amplification, particularly in the context of epithelial damage and immune dysfunction. While molecular diagnostics improve pathogen detection, they also complicate differentiation between colonisation and infection. Integrative approaches combining microbiology with host-response biomarkers, including markers of endothelial and microcirculatory dysfunction, enhance risk stratification and therapeutic decision-making.
Conclusions:
A host-response-integrated framework is essential to advance precision medicine in pneumonia and sepsis. Combining rapid diagnostics with phenotypic stratification may optimise antimicrobial use and enable targeted immunomodulation, improving outcomes while limiting unnecessary exposure.
Insights
Severe pneumonia and sepsis outcomes depend on host response, not just pathogens. Integrating host factors with diagnostics can personalize treatment for better patient results.
Area of Science:
- Critical care medicine
- Infectious diseases
- Immunology
Background:
- Severe pneumonia is a major cause of sepsis and death in critically ill patients.
- Pathogen-focused approaches fail to explain varied patient outcomes.
- Disease progression involves microbial load, host immune response, and environmental factors.
Purpose of the Study:
- To review current knowledge on pneumonia-to-sepsis progression.
- Focus on clinical phenotypes, host responses, and treatment strategies.
- Highlight the interaction between host and pathogen in severe infections.
Main Methods:
- Narrative review of recent literature (last decade, especially 2-3 years).
- Included PubMed-indexed studies, clinical trials, and guidelines.
- Focused on critically ill populations and host-pathogen interactions.
Main Results:
- Pneumonia presents diverse host-response phenotypes (hyperinflammatory to immunosuppressed).
- Viral infections and fungal opportunism worsen disease, especially with immune dysfunction.
- Integrative diagnostics (microbiology + host biomarkers) improve risk stratification.
Conclusions:
- A host-response framework is crucial for precision medicine in pneumonia and sepsis.
- Combining diagnostics and phenotypic data optimizes antimicrobial use and immunomodulation.
- Personalized treatment improves outcomes and reduces unnecessary drug exposure.
Related Concept Videos
01:29Pneumonia II: Pathophysiology
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:14Atypical Pneumonia
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: